Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Moving Points in Nephrology
You have accessRestricted Access

New Insights into Dialysis Vascular Access: Introduction

Michael Allon
CJASN August 2016, 11 (8) 1484-1486; DOI: https://doi.org/10.2215/CJN.01610216
Michael Allon
Division of Nephrology, University of Alabama at Birmingham, Birmingham, Alabama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • View PDF
Loading
  • arteriovenous access
  • arteriovenous fistula
  • arteriovenous graft
  • Arteriovenous Shunt
  • Surgical
  • Fluid Therapy
  • Problem Solving
  • renal dialysis

Optimizing vascular access outcomes continues to pose a tremendous challenge to nephrologists, surgeons, and radiologists who provide medical care to patients on hemodialysis. There is a huge discrepancy between the optimal vascular access outcome proposed by national guidelines (1) and the reality. Thus, for example, whereas the guidelines suggest that most patients should initiate hemodialysis with a mature arteriovenous fistula (AVF), approximately 80% of patients in the United States start dialysis with a central vein catheter (2). This discrepancy reflects both a poor understanding of the pathobiology of vascular access failure and a failure of the complex processes of care required to achieve optimal outcomes. Numerous studies published during the past few years have investigated both aspects of vascular access. In recognition of the huge clinical and economic effect of vascular access failure, the National Institutes of Diabetes, Digestive and Kidney Diseases convened a 2-day workshop in September of 2015 to address this critical topic (http://www.niddk.nih.gov/news/events-calendar/Pages/hemodialysis-vascular-access-2015.aspx). This workshop included nephrologists, surgeons, radiologists, basic scientists, and industry representatives with a common interest in vascular access research. This Moving Points series features three reviews related to topics presented at this workshop (3–5).

There is widespread consensus that a mature AVF is the access of choice for most patients on hemodialysis (1). However, a substantial proportion of new AVFs fails to mature adequately to be cannulated reproducibly with two large-bore needles thrice weekly and deliver the high blood flow required to achieve the target dialysis dose (Kt/V) (6,7). AVF maturation requires a sustained increase in the diameter and blood flow rate of the feeding artery and the draining vein to enable successful cannulation and adequate blood flow through the extracorporeal dialysis circuit (physiologic AVF maturation). Efforts to reduce AVF nonmaturation have been hampered by our poor understanding of its pathophysiology.

Previous animal and human studies of AVF nonmaturation have focused primarily on endothelial dysfunction and the venous neointimal hyperplasia that develops near the surgical anastomosis and leads to flow-limiting stenosis (inward remodeling). Experimental studies have identified a number of bioactive substances that modulate neointimal hyperplasia (8,9). This enhanced understanding of the pathobiology of neointimal hyperplasia may lead to novel pharmacologic therapies to promote AVF maturation. At the same time, there has been a growing recognition of the importance of the biologic processes leading to a sustained increase in the AVF lumen (outward remodeling). Ultimately, AVF maturation may depend on the balance between inward and outward remodeling (10). On the one hand, AVFs may mature, despite the development of anastomotic stenosis, as long as there is adequate outward remodeling. Thus, for example, in one clinical study, although AVF nonmaturation was more frequent in patients with stenosis than in those without stenosis, two thirds of AVFs with stenosis still matured without treatment of the stenosis (11). On the other hand, if outward remodeling is inadequate, an AVF will fail to mature, even in the absence of neointimal hyperplasia.

More recent studies have focused on the mechanisms of outward remodeling. Therapies that promote AVF maturation in animal models may not necessarily be effective in humans with AVF. Ultimately, only clinical trials will be able to establish potential pharmacologic approaches to enhancing AVF maturation. Ongoing trials are evaluating both therapies to prevent neointimal hyperplasia as well as ones to enhance outward remodeling. Two recent examples are the use of sirolimus-eluting wraps to prevent neointimal hyperplasia in new AVFs (12) and local application of elastase to the anastomotic site to promote sustained vasodilation (13). The paper by Lee and Misra (3) summarizes the exciting advances in our understanding of the complex pathophysiology of AVF nonmaturation.

Whereas the pathologic changes occurring after AVF maturation have long been recognized, there has been a more recent appreciation of preexisting arterial and venous pathology in patients with CKD. The vascular pathology described has included preexisting arterial and venous intimal hyperplasia, medial fibrosis, and arterial microcalcification (11,14–17). Several studies have evaluated whether these preexisting lesions contribute to poor AVF outcomes. Preexisting arterial and venous intimal hyperplasia may predispose to accelerated neointimal hyperplasia after AVF creation and thereby, lead to critical juxta–anastomotic stenosis and AVF nonmaturation. Preexisting arterial medial fibrosis and microcalcification may increase vascular stiffness, thereby limiting arterial dilation required for outward remodeling. Preexisting arterial intimal hyperplasia was associated with inferior AVF survival in one study (14), whereas preexisting venous intimal hyperplasia was not associated with juxta–anastomotic AVF stenosis at 6 weeks or clinical AVF maturation (11). Preexisting arterial microcalcification was not associated with postoperative AVF stenosis, AVF nonmaturation, or unassisted AVF patency in one prospective study (17). Finally, a study of patients receiving an arteriovenous graft (AVG) unexpectedly found that the frequency of AVG interventions (angioplasty, thrombectomy, or surgical revision) was actually lower in patients with greater preexisting arterial or venous intimal hyperplasia, arterial medial fibrosis, or arterial microcalcification (18). The manuscript by Vazquez-Padron and Allon (4) provides an overview of vascular pathology in patients with CKD and its relationship to vascular access outcomes.

Finally, notwithstanding the national guidelines on vascular access, there remains considerable uncertainty about their implementation. For example, the guidelines suggest that AVF creation should occur at least 6 months before the expected time of hemodialysis initiation to allow adequate time for AVF development and possible subsequent interventions to promote maturation (1). However, predicting time to dialysis remains notoriously difficult. If this time interval is overestimated, the patient is likely to initiate dialysis with a catheter. However, if the interval is underestimated, the patient may die before needing dialysis or have a very slow progression of kidney disease, such that the AVF is not needed. Several observational studies have reported that only about 70% of patients with CKD and predialysis access surgery will initiate dialysis within 2 years, with the remainder either dying before starting dialysis or surviving without a need for dialysis (19–21). Moreover, the patient outcomes are substantially affected by patient age, such that older patients with CKD have slower progression of their kidney disease and are less likely to die before they require dialysis (19).

In addition, there has been a growing sense that, although AVF may be the preferred vascular access, there may be subpopulations of patients in whom an AVG may be a better choice (22,23). In particular, AVG may be preferred in older patients who have already initiated dialysis with a catheter, have a high likelihood of AVF nonmaturation, or have had a prior failed AVF (22). The manuscript by Woo and Lok (5) addresses in detail issues related to the timing of vascular access surgery and the choice of access in patients with CKD and dialysis.

Disclosures

M.A. is a consultant for CorMedix, Bridgewater, NJ and Gore Medical, Flagstaff, AZ.

Acknowledgments

M.A. is supported by grant 1R21DK104248-01A1 from the National Institute of Diabetes, Digestive and Kidney Diseases.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • Copyright © 2016 by the American Society of Nephrology

References

  1. ↵
    KDOQI: KDOQI clinical practice guidelines and clinical practice recommendations for vascular access 2006. Am J Kidney Dis 48[Suppl 1]: S176–S322, 2006
    OpenUrlCrossRefPubMed
  2. ↵
    1. Collins AJ,
    2. Foley RN,
    3. Gilbertson DT,
    4. Chen SC
    : The state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysis. Clin J Am Soc Nephrol 4[Suppl 1]: S5–S11, 2009
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Lee T,
    2. Misra S
    : New insights into dialysis vascular access: Molecular targets in arteriovenous fistula and arteriovenous graft failure and their potential to improve vascular access outcomes. Clin J Am Soc Nephrol 11: 1504–1512, 2016
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Vazquez-Padron RI,
    2. Allon M
    : New insights into dialysis vascular access: Impact of preexisting arterial and venous pathology on AVF and AVG outcomes. Clin J Am Soc Nephrol 11: 1495–1503, 2016
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Woo K,
    2. Lok CE
    : New insights into dialysis vascular access: What is the optimal vascular access type and timing of access creation in CKD and dialysis patients? Clin J Am Soc Nephrol 11: 1487–1494, 2016
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Allon M
    : Current management of vascular access. Clin J Am Soc Nephrol 2: 786–800, 2007
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Dember LM,
    2. Beck GJ,
    3. Allon M,
    4. Delmez JA,
    5. Dixon BS,
    6. Greenberg A,
    7. Himmelfarb J,
    8. Vazquez MA,
    9. Gassman JJ,
    10. Greene T,
    11. Radeva MK,
    12. Braden GL,
    13. Ikizler TA,
    14. Rocco MV,
    15. Davidson IJ,
    16. Kaufman JS,
    17. Meyers CM,
    18. Kusek JW,
    19. Feldman HI
    ; Dialysis Access Consortium Study Group: Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: A randomized controlled trial. JAMA 299: 2164–2171, 2008
    OpenUrlCrossRefPubMed
  8. ↵
    1. Juncos JP,
    2. Tracz MJ,
    3. Croatt AJ,
    4. Grande JP,
    5. Ackerman AW,
    6. Katusic ZS,
    7. Nath KA
    : Genetic deficiency of heme oxygenase-1 impairs functionality and form of an arteriovenous fistula in the mouse. Kidney Int 74: 47–51, 2008
    OpenUrlCrossRefPubMed
  9. ↵
    1. Juncos JP,
    2. Grande JP,
    3. Kang L,
    4. Ackerman AW,
    5. Croatt AJ,
    6. Katusic ZS,
    7. Nath KA
    : MCP-1 contributes to arteriovenous fistula failure. J Am Soc Nephrol 22: 43–48, 2011
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Rothuizen TC,
    2. Wong C,
    3. Quax PH,
    4. van Zonneveld AJ,
    5. Rabelink TJ,
    6. Rotmans JI
    : Arteriovenous access failure: More than just intimal hyperplasia? Nephrol Dial Transplant 28: 1085–1092, 2013
    OpenUrlCrossRefPubMed
  11. ↵
    1. Allon M,
    2. Robbin ML,
    3. Young CJ,
    4. Deierhoi MH,
    5. Goodman J,
    6. Hanaway M,
    7. Lockhart ME,
    8. Litovsky S
    : Preoperative venous intimal hyperplasia, postoperative arteriovenous fistula stenosis, and clinical fistula outcomes. Clin J Am Soc Nephrol 8: 1750–1755, 2013
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Paulson WD,
    2. Kipshidze N,
    3. Kipiani K,
    4. Beridze N,
    5. DeVita MV,
    6. Shenoy S,
    7. Iyer SS
    : Safety and efficacy of local periadventitial delivery of sirolimus for improving hemodialysis graft patency: First human experience with a sirolimus-eluting collagen membrane (Coll-R). Nephrol Dial Transplant 27: 1219–1224, 2012
    OpenUrlCrossRefPubMed
  13. ↵
    1. Peden EK,
    2. Leeser DB,
    3. Dixon BS,
    4. El-Khatib MT,
    5. Roy-Chaudhury P,
    6. Lawson JH,
    7. Menard MT,
    8. Dember LM,
    9. Glickman MH,
    10. Gustafson PN,
    11. Blair AT,
    12. Magill M,
    13. Franano FN,
    14. Burke SK
    : A multi-center, dose-escalation study of human type I pancreatic elastase (PRT-201) administered after arteriovenous fistula creation. J Vasc Access 14: 143–151, 2013
    OpenUrlCrossRefPubMed
  14. ↵
    1. Kim YO,
    2. Song HC,
    3. Yoon SA,
    4. Yang CW,
    5. Kim NI,
    6. Choi YJ,
    7. Lee EJ,
    8. Kim WY,
    9. Chang YS,
    10. Bang BK
    : Preexisting intimal hyperplasia of radial artery is associated with early failure of radiocephalic arteriovenous fistula in hemodialysis patients. Am J Kidney Dis 41: 422–428, 2003
    OpenUrlCrossRefPubMed
    1. Lee T,
    2. Chauhan V,
    3. Krishnamoorthy M,
    4. Wang Y,
    5. Arend L,
    6. Mistry MJ,
    7. El-Khatib M,
    8. Banerjee R,
    9. Munda R,
    10. Roy-Chaudhury P
    : Severe venous neointimal hyperplasia prior to dialysis access surgery. Nephrol Dial Transplant 26: 2264–2270, 2011
    OpenUrlCrossRefPubMed
    1. Allon M,
    2. Litovsky S,
    3. Young CJ,
    4. Deierhoi MH,
    5. Goodman J,
    6. Hanaway M,
    7. Lockhart ME,
    8. Robbin ML
    : Medial fibrosis, vascular calcification, intimal hyperplasia, and arteriovenous fistula maturation. Am J Kidney Dis 58: 437–443, 2011
    OpenUrlCrossRefPubMed
  15. ↵
    1. Allon M,
    2. Robbin ML,
    3. Umphrey HR,
    4. Young CJ,
    5. Deierhoi MH,
    6. Goodman J,
    7. Hanaway M,
    8. Lockhart ME,
    9. Barker-Finkel J,
    10. Litovsky S
    : Preoperative arterial microcalcification and clinical outcomes of arteriovenous fistulas for hemodialysis. Am J Kidney Dis 66: 84–90, 2015
    OpenUrlCrossRefPubMed
  16. ↵
    1. Allon M,
    2. Litovsky S,
    3. Young CJ,
    4. Deierhoi MH,
    5. Goodman J,
    6. Hanaway M,
    7. Lockhart ME,
    8. Robbin ML
    : Correlation of pre-existing vascular pathology with arteriovenous graft outcomes in hemodialysis patients. Am J Kidney Dis 62: 1122–1129, 2013
    OpenUrlCrossRefPubMed
  17. ↵
    1. O’Hare AM,
    2. Bertenthal D,
    3. Walter LC,
    4. Garg AX,
    5. Covinsky K,
    6. Kaufman JS,
    7. Rodriguez RA,
    8. Allon M
    : When to refer patients with chronic kidney disease for vascular access surgery: Should age be a consideration? Kidney Int 71: 555–561, 2007
    OpenUrlCrossRefPubMed
    1. Oliver MJ,
    2. Quinn RR,
    3. Garg AX,
    4. Kim SJ,
    5. Wald R,
    6. Paterson JM
    : Likelihood of starting dialysis after incident fistula creation. Clin J Am Soc Nephrol 7: 466–471, 2012
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Lee T,
    2. Thamer M,
    3. Zhang Y,
    4. Zhang Q,
    5. Allon M
    : Outcomes of elderly patients after predialysis vascular access creation. J Am Soc Nephrol 26: 3133–3140, 2015
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Allon M,
    2. Lok CE
    : Dialysis fistula or graft: The role for randomized clinical trials. Clin J Am Soc Nephrol 5: 2348–2354, 2010
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Wish JB
    : Catheter last, fistula not-so-first. J Am Soc Nephrol 26: 5–7, 2015
    OpenUrlFREE Full Text
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 11 (8)
Clinical Journal of the American Society of Nephrology
Vol. 11, Issue 8
August 08, 2016
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
New Insights into Dialysis Vascular Access: Introduction
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
New Insights into Dialysis Vascular Access: Introduction
Michael Allon
CJASN Aug 2016, 11 (8) 1484-1486; DOI: 10.2215/CJN.01610216

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
New Insights into Dialysis Vascular Access: Introduction
Michael Allon
CJASN Aug 2016, 11 (8) 1484-1486; DOI: 10.2215/CJN.01610216
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Recommended Clinical Trial End Points for Dialysis Catheters
  • Clinical Trial End Points for Hemodialysis Vascular Access
  • Definitions and End Points for Interventional Studies for Arteriovenous Dialysis Access
Show more Moving Points in Nephrology

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Keywords

  • arteriovenous access
  • arteriovenous fistula
  • arteriovenous graft
  • Arteriovenous Shunt
  • surgical
  • fluid therapy
  • Problem Solving
  • renal dialysis

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals

© 2022 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire